Epidemija koronavirusa (Covid-19 / SARS-Cov2) - dnevne aktuelnosti iz zemlje i sveta

[Laki21]

7 hours ago, Ridji said:

Tek sad sam saznao da je samo postojanje tj posedovanje antitela dovoljno da se dobije kovid sertifikat, bez ikakvog drugog ispunjenog uslova. Doduse taj sertifikat vazi tri meseca ali opet mislio sam da postoji neki uslov sa zvanicnom potvrdom o prelezanosti virusa unazad u X meseci

 

5 hours ago, Romantik said:

 

Ja ga dobih prošle nedelje, s tim što su valjda skratili validnost na dva meseca, pre je bilo 3. E sad ono što ne znam je da li je moguće posle toga dobiti novi na još dva meseca ako su i dalje prisutna antitela.

 

Da li neko zna da li je ovo dovoljno da bi se priznalo za ulazak u EU (Hr i Slo konkretno)? I dalje sam (nakon druge doze Fajzera u martu) prepun AT, da sam makar znao ovo ranije pa da se testiram u INEPu a ne u Euromediku...

Edited December 13, 2021 by Laki21

[Akiro]

55 minutes ago, Sunshine State said:

 

Ja cu potegnuti svoje americke veze da @Akiropribavimo najzastitniju masku na svetu, nek mu se nadje...

Al' nek' se ne opusta previse!

 

@Prijatelj Mitar -u cemo omoguciti online pracenje....navik'o covek u skoli

 

Ove pelcovane Sputnjikom (da, da @Clash ) necemo primati - nije ih odobrila WHO, sto bismo mi?

 

 

Ako sve bude išlo kako valja,  pre ću učestvovati preko video-streama, što znači da ću svakako biti opušten. Ne moram da razmišljam ko je sekao hleb, salatu ili jagnjetinu.  

[erwin]

 

[shonke]

Pa trebalo bi da t-cells ovo, da t-cells ono a ovamo svi sto su se zarazili po nekim sastancima i party-jima bili vakcinisani. Pa gde sun im te t-cells?

Sent from my Redmi Note 7 using Tapatalk

[tomas.hokenberi]

6 hours ago, Laki21 said:

Da li neko zna da li je ovo dovoljno da bi se priznalo za ulazak u EU (Hr i Slo konkretno)? I dalje sam (nakon druge doze Fajzera u martu) prepun AT, da sam makar znao ovo ranije pa da se testiram u INEPu a ne u Euromediku

Ako posle testiranja u INEP-u to ulazi u "EU  kompatibilni digitalni kovid pasoš" možeš da proveriš očitavanjem QR koda hrvatskom i slovenačkom aplikacijom da li tamo važi i koliko dugo.

8 minutes ago, shonke said:

Pa trebalo bi da t-cells ovo, da t-cells ono a ovamo svi sto su se zarazili po nekim sastancima i party-jima bili vakcinisani. Pa gde sun im te t-cells?

Sent from my Redmi Note 7 using Tapatalk
 

Pa valjda T-cells reaguju kada se zaraziš i deluju tada protiv virusa te su posledice zaraze najcesce male ili nikakve, ne deluju kao neprobojna barijera koja sprečava zarazu. 

[erwin]

Dva grafika za Gauteng, prvo jedan koji pokazuje da je udeo hospitalizovanih na respiratoru (najbliži parametar za procenu smrtnosti) sada 3x manji nego tokom talasa delte (pik slučajeva bio je 8. jula), što približno odgovara onoj 3,5x manjoj smrtnosti koju je grafički prikazao FT-jev novinar Merdok:

 

 

Izvor:
https://twitter.com/rorynotsorry/status/1470488424570359824

 

Lik je entuzijasta koji je povadio podatke iz zvaničnih dnevnih izveštaja i iscrtao ovo.

 

Drugi grafik potiče od tamošnjeg epidemiologa i pokazuje da hospitalizacije i smrti u Gautengu i dalje ne dostižu iste visine kao kod delte - grafik je normalizovan na maksimume slučajeva, hospitalizacija i smrti tokom talasa delte.

 

 

Izvor:

https://twitter.com/hivepi/status/1470645434263736322 

 

I na kraju svež Bloombergov članak u kome stručnjaci i dalje upozoravaju da je prava težina omikrona možda skrivena zbog velikog prethodnog imuniteta.

 

 

Edited December 14, 2021 by erwin

[erwin]

 

 

[erwin]

Neki od slajdova iz gornjeg niza:

 

 

 

 

 

 

 

 

 

 

 

Edited December 14, 2021 by erwin

[erwin]

Ako nekog zanima da odgleda celu prezentaciju:

 

Quote

Link to Media webinar:

Topic: Media Briefing 14 Dec at 11am: Discovery Health releases first at-scale analysis of real-world experience of Omicron outbreak from South Africa

Start Time: Dec 14, 2021 10:33 AM

Meeting Recording:

https://dsycloud.zoom.us/rec/share/F90e3WwsG3hnWohegHBLZ794OqtadWO5wNTEMh-5BE7uIG-G_Rlex4WT0wtBJHtM.jBJNHyH9YLBdybjJ

Access Passcode: .=Q8e3aQ

https://www.discovery.co.za/corporate/news-room

Edited December 14, 2021 by erwin

[erwin]

Vanredni profesor epidemiologije sa Harvarda, bavi se dinamikom zaraznih bolesti:

 

 

 

 

 

 

Edited December 14, 2021 by erwin

[erwin]

Sa PPP-a, jedan forumaš piše o dogodovštinama u Kini:

Quote

sinoc sam bio na jednoj lokaciji u sangaju kada su iz ministarstva vanjskih poslova javili da se u susednoj zgradi pojavio zarazeni japanac. obicno u takvim slucajevima zatvaraju kvartal, kako nas ne bi zatvorili na 2-3 nedelje, oma sam sa koleginicom iskljucio telefon i izleteli na ulicu. kada smo izasli iz gated community prvo smo skrenuli levo, ali prema nama su (svojim poslom) isli ljudi u belom sa maskama, tako da smo napravili 180 stepeni i krenuli desno, nasli taksi i vozi misko. inace, svi zovu taksi preko mobilnog, ali smo imali srece da naletimo na parkirano vozilo.

za sat vremena su nam sa lokacije javili da su zatvorili samo tri zgrade i vec je bio sator sa ekipom za testiranje. 

sada je frka kako ce nam se odraziti u mobilnim aplikacijama. jer dok imas zeleni kod sve je ok, ali ako si nandzarasti ili crvenkast to je problem i kada se vratim u peking mogu biti karantinisan.
juce sam radio test, danas jos jedan i planiram da letim za ostrvo hainan. ako me  puste trebalo bi da je sve ok, ako tamo zaglavim karantin nece mi tesko pasti, samo da imam terasu sa pogledom na more. 
kod je trenutno zelen, ali pise da sam bio u krajevima sangaja koju su pod rizikom. peking ulazi u paranoicnu fazu zbog olimpijade i bolje da se ne izlazi iz grada, ali ja moram zbog posla

Edited December 14, 2021 by erwin

[erwin]

Balazs Lab, 2h, 16 tweets, 7 min read 
Until the pre-print posts, I figured I would put together a thread for those who want to see the data. Many thanks to @wilfredo_nk, @kstdenis29, @EvanCLam, @adamnitido, @NaranbhaiVivek who have been up at all hours of the night both at the bench and writing the paper!
 
We generated harmless pseudoviruses decorated with spikes that represent circulating Delta and Omicron spike proteins. Compared to the Wuhan isolate, Delta has 9 mutations in spike, but Omicron has 34!
 



When we map these mutations onto the structure of SARS-CoV-2 spike protein it's clear that many of these cluster together near the "top" of the spike, in regions exposed to neutralizing antibodies.
 



We tested 239 samples from people who were fully vaccinated with Moderna, Pfizer or J&J. Within these groups we had people who were recently vaccinated, who got their shot 6-12 mo ago, or who were recently boosted. We also separated people with prior infection.
 



We used a robot-based neutralization assay to quickly measure the activity of samples as compared to the WHO standard.
 



Here's what we saw for people who got Moderna: 
 



Here's what the data looked like for people who got Pfizer:
 



Here's what it looked like for people who got J&J:
  



When we directly compared neutralization of the original Wuhan isolate by people who hadn't or had been boosted, we saw fairly small differences for mRNA vaccines and a fairly large one for J&J.
 



What was really surprising was that an mRNA booster made a huge difference in the ability of people to neutralize Omicron. 

 



We also checked the infectivity of our pseudoviruses and saw clear differences between the variant strains we tested, with Omicron showing greater ability to infect cells than any other variant.
 



When we quantified the slopes of these infections, we found that Omicron was almost 4 times more infectious than the original strain. Even more than Delta!




Overall, our findings suggest that boosting is doing a lot more than simply increasing your titers. It seems to be broadening the antibody response to be better equipped to recognize diverse variants. Hopefully it will still work against whatever variant comes next!
 
I want to stress that all of this work has been done with pseudovirus which is a model of coronavirus, but there are plenty of caveats in measurements like ours. Keep in mind that the virus has plenty of other immune responses to contend with (like T cells or NK cells).
 
I also want to be sure to thank all of our incredible collaborators at @MGHPathology and @ragoninstitute including @blakemhauser, Jared Feldman and of course the entire @SchmidtLabHMS. Also thanks to the @MassCPR for their support!
 
For the curious few who may want to have the pre-print before it's available on MedRxiv, I've posted it to our lab webpage here:
 balazslab.partners.org/publications.h…
 All of our spike expression plasmids are with @Addgene now and should be available to distribute shortly!  

https://threadreaderapp.com/thread/1470726999538745355.html

[erwin]

 

[erwin]

Fajzerova pilula po finalnim rezultatima 89% efikasna protiv hospitalizacije i smrti, a izgleda i da deluje na omikron.

 

 

Quote

PFIZER ANNOUNCES ADDITIONAL PHASE 2/3 STUDY RESULTS CONFIRMING ROBUST EFFICACY OF NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE IN REDUCING RISK OF HOSPITALIZATION OR DEATH

Tuesday, December 14, 2021 - 06:45am

Final data available from all high-risk patients enrolled in EPIC-HR study (n= 2,246) confirmed prior results of interim analysis showing PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo; no deaths compared to placebo in non-hospitalized, high-risk adults with COVID-19

The above data have been shared with the U.S. Food and Drug Administration (FDA) as part of an ongoing rolling submission for Emergency Use Authorization (EUA)

Separately, interim analyses of an ongoing second study in standard-risk adults (EPIC-SR) showed a 70% reduction in hospitalization and no deaths in the treated population, compared to placebo, in the secondary endpoint; the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days, as compared to placebo, was not met. The study continues

An approximate 10-fold decrease in viral load at Day 5, relative to placebo, was observed in both EPIC-HR and EPIC-SR, indicating robust activity against SARS-CoV-2 and representing the strongest viral load reduction reported to date for a COVID-19 oral antiviral agent

Recent in vitro data confirm that nirmatrelvir is a potent inhibitor of the Omicron 3CL protease, which, combined with existing in vitro antiviral and protease inhibition data from other Variants of Concern (VoC) including Delta, indicates that PAXLOVID will retain robust antiviral activity against current VoCs as well as other coronaviruses

 

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). These results were consistent with the interim analysis announced in November 2021, showing PAXLOVID significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset. In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in the interim analysis. The EPIC-HR data have been shared with the U.S. Food and Drug Administration (FDA) as part of an ongoing rolling submission for Emergency Use Authorization (EUA).

“This news provides further corroboration that our oral antiviral candidate, if authorized or approved, could have a meaningful impact on the lives of many, as the data further support the efficacy of PAXLOVID in reducing hospitalization and death and show a substantial decrease in viral load. This underscores the treatment candidate’s potential to save the lives of patients around the world,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic.”

EPIC-HR Final Results

In the final analysis of the primary endpoint from all patients enrolled in EPIC-HR, an 89% reduction in COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset was observed, consistent with the interim analysis. In addition, a consistent safety profile was observed.

0.7% of patients who received PAXLOVID were hospitalized through Day 28 following randomization (5/697 hospitalized with no deaths), compared to 6.5% of patients who received placebo and were hospitalized or died (44/682 hospitalized with 9 subsequent deaths). The statistical significance of these results was high (p<0.0001). In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset; 0.8% of patients who received PAXLOVID were hospitalized or died through Day 28 following randomization (8/1039 hospitalized with no deaths), compared to 6.3% of patients who received placebo (66/1046 hospitalized with 12 subsequent deaths), with high statistical significance (p<0.0001). Relative risk reduction was 94% in patients 65 years of age or older, one of the populations at highest risk for hospitalization or death; 1.1% of patients who received PAXLOVID were hospitalized through Day 28 (1/94 hospitalized with no deaths), compared to 16.3% of patients who received placebo (16/98 hospitalized with 6 deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID as compared to 12 (1.2%) deaths in patients who received placebo.

In the EPIC-HR trial, in a secondary endpoint, SARS-CoV-2 viral load at baseline and Day 5 have been evaluated for 499 patients. After accounting for baseline viral load, geographic region, and serology status, PAXLOVID reduced viral load by approximately 10-fold, or 0.93 log10 copies/mL, relative to placebo, indicating robust activity against SARS-CoV-2 and representing the strongest viral load reduction reported to date for an oral COVID-19 agent.

Treatment-emergent adverse events were comparable between PAXLOVID (23%) and placebo (24%), most of which were mild in intensity. Fewer serious adverse events (1.6% vs. 6.6%) and discontinuation of study drug due to adverse events (2.1% vs. 4.2%) were observed in patients dosed with PAXLOVID, compared to placebo, respectively.

All other secondary endpoints for this study, which are available on clinicaltrials.gov (NCT04960202), were not yet available for this review. Full study data are expected to be released later this month and submitted to a peer-reviewed publication.

EPIC-SR Interim Results

Interim analyses of the EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) Phase 2/3 study, which included unvaccinated adults who were at standard risk (i.e., low risk of hospitalization or death) as well as vaccinated adults who had one or more risk factors for progressing to severe illness, showed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days, as compared to placebo, was not met.

The key secondary endpoint showed a 70% reduction in hospitalization and no deaths in the treated population for any cause compared to placebo. Additionally, there was approximately a 10-fold, or 1 log10 copies/mL, decrease in viral load compared to placebo, consistent with results from the Phase 2/3 EPIC-HR study.

The data were reviewed by an independent Data Monitoring Committee (DMC) and, based on the totality of the data available, the DMC recommended that the trial continue.

At the EPIC-SR interim analysis, which included 45% of the trial’s planned enrollment, 0.6% of those who received PAXLOVID were hospitalized following randomization (2/333 hospitalized with no deaths), compared to 2.4% of patients who received placebo and were hospitalized or died (8/329 hospitalized with no deaths). A follow-on analysis at 80% of enrolled patients was consistent with these findings. In this analysis, 0.7% of those who received PAXLOVID were hospitalized following randomization (3/428 hospitalized with no deaths), compared to 2.4% of patients who received placebo and were hospitalized or died (10/426 hospitalized with no deaths); p=0.051.

Treatment-emergent adverse events were comparable between PAXLOVID (22%) and placebo (21%), most of which were mild in intensity. Rates of serious adverse events (1.4% vs. 1.9%) and discontinuation of study drug due to adverse events (2.1% vs. 1.2%) were also comparable between PAXLOVID and placebo.

All other secondary endpoints for this study, which are available on clinicaltrials.gov (NCT05011513), were not yet available for this review. The study is now fully enrolled, and further data will be released upon analysis of the full study data expected later this month.

About PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)

PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy. It was developed to be administered orally so that, if authorized or approved, it can be prescribed at the first sign of infection or at first awareness of an exposure – potentially helping patients avoid severe illness (which can lead to hospitalization and death) or avoid disease development following contact with a household member who contracts COVID-19 – subject to the clinical success of the rest of the EPIC development program. Nirmatrelvir [PF-07321332], which originated in Pfizer laboratories, is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Current variants of concern can be resistant to treatments that are focused on the spike protein expressed on the surface of the SARS-CoV-2 virus, due to the mutations in this region. PAXLOVID, however, works intracellularly on the protease of the SARS-CoV-2 virus by inhibiting viral replication. Nirmatrelvir has shown consistent in vitro antiviral activity against the previously identified variants of concerns (i.e., alpha, beta, delta, gamma, lambda, and mu). In addition, nirmatrelvir potently inhibited the 3CL protease associated with Omicron in an in vitro biochemical assay. This indicates nirmatrelvir’s potential to maintain robust antiviral activity against Omicron. Additional in vitro antiviral studies with this variant are underway.

If authorized or approved, PAXLOVID will be administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days. One box contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.

About the Phase 2/3 EPIC-HR Study Top-Line Results

The final analysis of the primary endpoint evaluated data from 2,246 adults who were enrolled by November 4, 2021. At the time of the decision to stop recruiting patients, enrollment was at 75% of the 3,000 planned patients from clinical trial sites across North and South America, Europe, Africa, and Asia, with 41% of patients located in the United States. Enrolled individuals had a laboratory-confirmed diagnosis of mild to moderate SARS-CoV-2 infection within a five-day period and were required to have at least one characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19. Each patient was randomized (1:1) to receive PAXLOVID or placebo orally every 12 hours for five days.

About the Phase 2/3 EPIC-SR Study Interim Analyses

The primary analysis of the interim data, consisting of the first 45% of patients enrolled in the study, included 673 adults, of whom 338 received PAXLOVID and 335 received placebo. At the time of the interim analyses, EPIC-SR had reached its planned enrollment of more than 1,140 adults from clinical trial sites across North and South America, Europe, Africa, and Asia, and the United States. Enrolled individuals had a laboratory-confirmed diagnosis of mild to moderate SARS-CoV-2 infection within a five-day period and were either unvaccinated adults who were at standard risk (i.e., low risk of hospitalization or death) or vaccinated adults who had one or more risk factors for progressing to severe illness from COVID-19. Each patient was randomized (1:1) to receive PAXLOVID or placebo orally every 12 hours for five days.

About the EPIC Development Program

The EPIC (Evaluation of Protease Inhibition for COVID-19) Phase 2/3 development program for nirmatrelvir; ritonavir consists of three clinical trials spanning a broad spectrum of patients, including adults who have been exposed to the virus through household contacts, as well as adults at both standard risk and high risk of progressing to severe illness.

In July 2021, Pfizer initiated the first of these trials, known as EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients), a randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer ceased further enrollment into the study in early November 2021 due to the overwhelming efficacy demonstrated in results from an interim analysis. Data have been submitted to the FDA as part of its submission for Emergency Use Authorization, and findings from the EPIC-HR interim analysis have been submitted to a peer-reviewed journal for publication.

In August 2021, Pfizer began the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients), to evaluate efficacy and safety in patients with a confirmed diagnosis of SARS-CoV-2 infection who are at standard risk (i.e., low risk of hospitalization or death).

In September, Pfizer initiated the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) to evaluate efficacy and safety in adults exposed to SARS-CoV-2 by a household member. This trial is ongoing.

For more information on the EPIC Phase 2/3 clinical trials for PAXLOVID, visit clinicaltrials.gov.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results

Edited December 14, 2021 by erwin

[zoe Bg]

1547/15635/32

 

Na respiratoru 146

 

U bolnicama 2930

[erwin]

 

[Kronostime]

50 minutes ago, zoe Bg said:

1547/15635/32

 

Na respiratoru 146

 

U bolnicama 2930

Jos uvek - previse.

[erwin]

 

[Sunshine State]

@Devil In My Pants - kako supruga, sve ok?

 

@Stiletto - kako sin i cerka?

 

@AgroLaki - kako mama i tata?

 

 

 

 

[Prijatelj Mitar]

23 minutes ago, Sunshine State said:

@Devil In My Pants - kako supruga, sve ok?

 

@Stiletto - kako sin i cerka?

 

@AgroLaki - kako mama i tata?

 

 

 

 

 

@Kronostime - kako svastika? 

[Devil In My Pants]

54 minutes ago, Sunshine State said:

@Devil In My Pants - kako supruga, sve ok?

 

@Stiletto - kako sin i cerka?

 

@AgroLaki - kako mama i tata?

 

 

 

 

Hvala na pitanju za sad je sve ok, juce malo temperatura,ali nista, sad je vec dobro. Da kucnem u drvo..jos manje od 30 dana :))

[Kronostime]

1 hour ago, Prijatelj Mitar said:

 

@Kronostime - kako svastika? 

Za koju pitujes, mori - imam ih vise?

[Prijatelj Mitar]

26 minutes ago, Kronostime said:

Za koju pitujes, mori - imam ih vise?

 

 

🙂

[Kronostime]

2 minutes ago, Prijatelj Mitar said:

 

 

🙂

Ove iz tvoju struku sve udovice - pa  ako bi` da se usrecis....

[40Wins]

2 hours ago, Sunshine State said:

 

@AgroLaki - kako mama i tata?

 

 

Hvala na pitanju! 🙂 Jucer su zavrsili sa izolacijom, cale isprimao 10 heparina, danas je valjda davao CRP ponovo, keva ce za 10 dana drugi put i to je u sustini. A da, cale jos valjda nije ispio pronizon.

Sad polako oporavak i valjda je ostao samo Ddimer da motre na njega jer su stariji, ali s obzirom da im je ispod 1000, mislim da nisu u nekom znacajnom riziku kao kad ljudima skoci na vise hiljada. Verovatno je 3x vakcina odradila svoje da ne bude preterano. Jos sam oprezan, ali to mu valjda dodje to.

Sa ovim sam zavrsio ceo zenin i moj uzi krug roditelji, braca, sestre itd + nas dvoje,  sto se tice razboljevanja, tako da se nadam da od 2022. mogu da kazem da je korola iza mene, sto se tice straha od nekih ozbiljnijih simptoma za najblize.